Transforming growth factor-β in human glomerular injury

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 4, 1997, Pages 389-393

  Peters, Harm ^a   Noble, Nancy A ^a   Border, Wayne A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE THERAPY; GLOMERULOPATHY; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; PRIORITY JOURNAL; PROTEIN RESTRICTION; RECEPTOR BLOCKING; REVIEW; WOUND HEALING;

EID: 0030848918     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199707000-00014     Document Type: Review

References (27)

1. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988, 318:1657-1666.
2. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
3. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990, 346:371-374.
4. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994, 45:916-927.
5. Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol (in press).
6. Sharma K, Jin Y, Quo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530. This study demonstrates that TGF-B has a causal role in the extracellular matrix accumulation and renal hypertrophy seen in early diabetic nephropathy.
7. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS: Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003. Using transgenic mice overexpressing the TGF-ß1 gene in the liver, this study showed that increased plasma levels of TGF-ß1 result in progressive renal fibrosis and death from renal failure.
8. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
9. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49:461-469. Using human renal biopsy specimens, this study conclusively relates TGF-ß overproduction to matrix deposition in a number of human renal diseases.
10. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA: Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995, 6:286-294.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
12. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994, 23:247-254.
13. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992, 140:95-107.
14. Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK: Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A 1991, 88:1928-1932.
15. Zelezna B, Rydzewski B, Lu D, Olson JA, Shiverick KT, Tang W, Sumners C, Raizada MK: Angiotensin-II induction of plasminogen activator inhibitor-1 gene expression in astroglial cells of normotensive and spontaneously hypertensive rat brain. Mol Endocrinol 1992, 6:2009-2017.
16. Kagami S, Kuhura T, Okuda K, Border WA, Noble NA: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51:664-671. PAI-1 is an important inhibitor of the matrix degrading plasminogen/plasmin system. This paper presents in-vitro data demonstrating that Ang II has an early direct effect on PAI-1 expression and that sustained PAI-1 upregulation is mediated through induction of TGF-ß synthesis.
17. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid Smith PS: The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989, 321:1773-1777.
18. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1991, 88:9765-9769.
19. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990, 137:1323-1332.
20. Nakayama M, Okuda S, Tamaki K, Fujishima M: Short- or long-term effects of a low-protein diet on fibronectin and transforming growth factor-beta synthesis in adriamycin-induced nephropathy. J Lab Clin Med 1996, 127:29-39.
21. Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 1995, 72:17-24.
22. Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA: L-Arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci U S A 1995, 92:4552-4556.
23. Ketteler M, Ikegaya N, Brees DK, Border WA, Noble NA: L-Arginine metabolism in immune-mediated glomerulonephritis in the rat. Am J Kidney Dis 1996, 28:878-887. This study shows that, in acute ATS-induced glomerulonephritis, sequential activation of metabolic L-arginine pathways is closely linked to tissue injury (NO), cell proliferation (polyamines), and collagen synthesis (L-proline)
24. Ketteler M, Border WA, Noble NA: Cytokines and L-arginine in renal injury and repair. Am J Physiol 1994, 267:F197-F207.
25. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991, 40:195-202.
26. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi YU, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360:361-364.
27. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996, 2:418-423. This studly presents conclusive data demonstrating that decorin gene therapy is a highly effective new approach in preventing renal fibrosis.